TY - JOUR
T1 - The effects of 3% diquafosol sodium eye drop application on meibomian gland and ocular surface alterations in the Cu, Zn-superoxide dismutase-1 (Sod1) knockout mice
AU - Ikeda, Keisuke
AU - Simsek, Cem
AU - Kojima, Takashi
AU - Higa, Kazunari
AU - Kawashima, Motoko
AU - Dogru, Murat
AU - Shimizu, Takahiko
AU - Tsubota, Kazuo
AU - Shimazaki, Jun
N1 - Funding Information:
Conflict of interest Kazuo Tsubota is a consultant, on the speaker’s bureau and has received grant support from Santen Pharmaceutical Co., Ltd. that is unrelated to the contents of this research. All the other authors certify that they have no affiliations with or involvement in any or entity with any financial interest such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements, or non-financial interest such as personal or professional relationships, affiliations, knowledge, or beliefs in the subject matter or materials discussed in this manuscript.
Funding Information:
Acknowledgements This work was supported by a grant from Santen Pharmaceuticals.
Publisher Copyright:
© 2018, Springer-Verlag GmbH Germany, part of Springer Nature.
PY - 2018/4/1
Y1 - 2018/4/1
N2 - Purpose: The purpose of the study is to investigate the effect of 3% diquafosol sodium eye drops on meibomian gland and ocular surface alterations in the superoxide dismutase-1 (Sod1−/−) mice in comparison to the wild-type mouse. Methods: Three percent diquafosol sodium eye drop was instilled to 20 eyes of 10 50-week-old male Sod1−/− mice and 22 eyes of 11 C57BL/6 strain 50-week-old wild-type (WT) male mice six times a day for 2 weeks. Aqueous tear secretion quantity was measured with phenol red-impregnated cotton threads without anesthesia. Tear film stability and corneal epithelial damage were assessed by fluorescein and lissamine green staining. We also performed oil red O (ORO) lipid staining to evaluate the lipid changes in the meibomian glands. Meibomian gland specimens underwent hematoxylin and eosin staining to examine histopathological changes and meibomian gland acinar unit density after sacrifice. Immunohistochemistry staining was performed using cytokeratin 4, cytokeratin 13, and transglutaminase-1 antibodies. Quantitative real-time polymerase chain reaction for cytokeratin 4, cytokeratin 13, and transglutaminase-1 mRNA expression was also performed. Results: The aqueous tear quantity, the mean tear film breakup time, and the number of lipid droplets significantly improved in the Sod1−/− mice with treatment. The mean meibomian acinar unit density did not change in the Sod1−/− mice and WT mice after treatment. Application of 3% diquafosol sodium eye drop significantly decreased the corneal fluorescein and lissamine green staining scores in the Sod1−/− mice after 2 weeks. We showed a notable increase in cytokeratin 4, cytokeratin 13 immunohistochemistry staining, and cytokeratin 4, cytokeratin 13 mRNA expressions with a marked decrease in immunohistochemistry staining and significant decline in mRNA expression of transglutaminase-1 after 3% diquafosol sodium treatment. Conclusion: Topical application of 3% diquafosol sodium eye drop improved the number of lipid droplets, tear stability, and tear production which in turn appeared to have a favorable effect on the ocular surface epithelium. Three percent diquafosol sodium eye drop may be a potential treatment for age-related meibomian gland and dry eye disease based on the observations of the current study.
AB - Purpose: The purpose of the study is to investigate the effect of 3% diquafosol sodium eye drops on meibomian gland and ocular surface alterations in the superoxide dismutase-1 (Sod1−/−) mice in comparison to the wild-type mouse. Methods: Three percent diquafosol sodium eye drop was instilled to 20 eyes of 10 50-week-old male Sod1−/− mice and 22 eyes of 11 C57BL/6 strain 50-week-old wild-type (WT) male mice six times a day for 2 weeks. Aqueous tear secretion quantity was measured with phenol red-impregnated cotton threads without anesthesia. Tear film stability and corneal epithelial damage were assessed by fluorescein and lissamine green staining. We also performed oil red O (ORO) lipid staining to evaluate the lipid changes in the meibomian glands. Meibomian gland specimens underwent hematoxylin and eosin staining to examine histopathological changes and meibomian gland acinar unit density after sacrifice. Immunohistochemistry staining was performed using cytokeratin 4, cytokeratin 13, and transglutaminase-1 antibodies. Quantitative real-time polymerase chain reaction for cytokeratin 4, cytokeratin 13, and transglutaminase-1 mRNA expression was also performed. Results: The aqueous tear quantity, the mean tear film breakup time, and the number of lipid droplets significantly improved in the Sod1−/− mice with treatment. The mean meibomian acinar unit density did not change in the Sod1−/− mice and WT mice after treatment. Application of 3% diquafosol sodium eye drop significantly decreased the corneal fluorescein and lissamine green staining scores in the Sod1−/− mice after 2 weeks. We showed a notable increase in cytokeratin 4, cytokeratin 13 immunohistochemistry staining, and cytokeratin 4, cytokeratin 13 mRNA expressions with a marked decrease in immunohistochemistry staining and significant decline in mRNA expression of transglutaminase-1 after 3% diquafosol sodium treatment. Conclusion: Topical application of 3% diquafosol sodium eye drop improved the number of lipid droplets, tear stability, and tear production which in turn appeared to have a favorable effect on the ocular surface epithelium. Three percent diquafosol sodium eye drop may be a potential treatment for age-related meibomian gland and dry eye disease based on the observations of the current study.
KW - Diquafosol
KW - Dry eye
KW - Meibomian gland alterations
KW - Oxidative stress
UR - http://www.scopus.com/inward/record.url?scp=85042537763&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85042537763&partnerID=8YFLogxK
U2 - 10.1007/s00417-018-3932-x
DO - 10.1007/s00417-018-3932-x
M3 - Article
C2 - 29484560
AN - SCOPUS:85042537763
SN - 0721-832X
VL - 256
SP - 739
EP - 750
JO - Graefe's Archive for Clinical and Experimental Ophthalmology
JF - Graefe's Archive for Clinical and Experimental Ophthalmology
IS - 4
ER -